Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

aldastotug

A humanized monoclonal antibody targeting the immune checkpoint molecule sialic acid-binding immunoglobulin (Ig)-like lectin 15 (Siglec-15; SIGLEC15; S15; CD33L3), with potential immune checkpoint inhibitory, antineoplastic and immunomodulatory activities. Upon administration, aldastotug targets and binds to S15 on the surface of tumor-associated macrophages (TAMs) and certain tumor cells. Binding to S15 may disrupt TAM-mediated activities such as promotion of tumor initiation and metastasis of tumor cells and inhibition of CD8-positive and CD4-positive T-cell responses. This leads to activation of the immune system and an inhibition of tumor cell growth. S15, a highly conserved type 1 cell surface protein, normally involved in osteoclast differentiation and bone remodeling, is overexpressed on and may play a key role in the survival and differentiation of TAMs and various tumor cells.
Synonym:anti-S15 monoclonal antibody PYX-106
anti-Siglec-15 monoclonal antibody BSI-060T
anti-Siglec-15 monoclonal antibody PYX-106
Code name:BSI 060T
BSI-060T
BSI060T
PYX 106
PYX-106
PYX106
Search NCI's Drug Dictionary